Evidence map›Paper›PMID 36705285›Full record

ArticleJournal of managed care & specialty pharmacy2023

Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement.

Samuel K Peasah, Yan Huang, Swetha R Palli, Elizabeth Cs Swart, Bonnie Mk Donato, Pratik Pimple, Jacqueline Bovier, Chronis Manolis, Chester B Good

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Samuel K PeasahCenter for High-Value Health Care, UPMC Health Plan, Pittsburgh, PA.
Yan HuangCenter for High-Value Health Care, UPMC Health Plan, Pittsburgh, PA.
Swetha R PalliBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
Elizabeth Cs SwartCenter for High-Value Health Care, UPMC Health Plan, Pittsburgh, PA.
Bonnie Mk DonatoBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
Pratik PimpleBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
Jacqueline BovierPharmacy services, UPMC Health Plan, Pittsburgh, PA.
Chronis ManolisPharmacy services, UPMC Health Plan, Pittsburgh, PA.
Chester B GoodCenter for High-Value Health Care, UPMC Health Plan, Pittsburgh, PA.
Boehringer Ingelheim (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Medicare Part CAdultAgedBenzhydryl CompoundsGlucosidesHealth Care CostsHumansProspective StudiesRetrospective StudiesUnited StatesBenzhydryl CompoundsempagliflozinGlucosides

Identifiers

PMID36705285
PMCPMC10387982
OpenAlexW4318263493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.